medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (3)


Choroidal neovascularization with interferon associated retinopathy: Case report and review of literature

Bazarah SM, Ritenour R, Patel ST, Hirsch G, Peltekian KM, Cruess AF

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 172-176
Archivo PDF: 173.24 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.

  2. Willson RA. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. J Clin Gastroenterol 2004; 38: 717-22.

  3. Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol 2004; 18: 715-28.

  4. d’Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61.

  5. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82: 323-5.

  6. Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J, Tang RA, Marmor M, Abrams G, Miller JW, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350-6.

  7. Nishiwaki H, Ogura Y, Miyamoto K, Matsuda N, Honda Y. Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996; 114: 726-30.

  8. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93: 2441-4.

  9. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79: 150-2.

  10. Abe T, Nakajima A, Satoh N, Koizumi T, Sakuragi S, Ono T, Komatsu M, Masamune O. Clinical characteristics of hepatitis C virus-associated retinopathy. Jpn J Ophthalmol 1995; 39: 411-9.

  11. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol 2001; 119 : 1077-9.

  12. Zegans ME, Anninger W, Chapman C, Gordon SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002; 13: 423-7.

  13. Isaac A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67.

  14. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689-96.

  15. Sundmacher R, Cantell K, Skoda R, Hallermann C, Neumann-Haefelin D. Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978; 208: 229-33.

  16. Fung WE. Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol 1991; 112: 349-50.

  17. Gillies M, Francis I, McCluskey P, Wakefield D. Local interferon alfa-2b for ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 927.

  18. Gillies MC, Brooks AM, Young S, Gillies B, Simpson JM, Goldberg I. A randomized phase II trial of interferon-alpha2b versus 5-fluorouracil after trabeculectomy. Aust N Z J Ophthalmol 1999; 27: 37-44.

  19. Ikebe T, Nakatsuka K, Goto M, Sakai Y, Kageyama S. A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn (Ganka-Kiyo) 1990; 41: 2291-6.

  20. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 1171-1173 .

  21. Cuthbertson FM, Davies M , McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88: 1518-1520.




2020     |     www.medigraphic.com